[go: up one dir, main page]

NO20045072L - Tablett med hoyt medikamentinnhold - Google Patents

Tablett med hoyt medikamentinnhold

Info

Publication number
NO20045072L
NO20045072L NO20045072A NO20045072A NO20045072L NO 20045072 L NO20045072 L NO 20045072L NO 20045072 A NO20045072 A NO 20045072A NO 20045072 A NO20045072 A NO 20045072A NO 20045072 L NO20045072 L NO 20045072L
Authority
NO
Norway
Prior art keywords
tablet
high drug
drug content
weight
formula
Prior art date
Application number
NO20045072A
Other languages
English (en)
Other versions
NO341027B1 (no
Inventor
Jorg Ogorka
Oskar Kalb
Christian-Peter Luftensteiner
Jean-Claude Bianchi
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9935351&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20045072(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20045072L publication Critical patent/NO20045072L/no
Publication of NO341027B1 publication Critical patent/NO341027B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C43/00—Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor
    • B29C43/003—Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor characterised by the choice of material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Mechanical Engineering (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Den foreliggende oppfinnelsen vedrører en tablett med høyt medikamentinnhold omfattende som aktiv ingrediens forbindelse I av formel (1) eller et farmasøytisk akseptabelt salt derav i en mengde fra omkring 30% til 80 vekt-% av den aktive delen basert på totalvekten av tabletten.
NO20045072A 2002-04-23 2004-11-22 Tablett med høyt medikamentinnhold og fremgangsmåte for fremstilling derav NO341027B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0209265A GB0209265D0 (en) 2002-04-23 2002-04-23 Organic compounds
PCT/EP2003/004151 WO2003090720A1 (en) 2002-04-23 2003-04-22 High drug load tablet

Publications (2)

Publication Number Publication Date
NO20045072L true NO20045072L (no) 2005-01-20
NO341027B1 NO341027B1 (no) 2017-08-07

Family

ID=9935351

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045072A NO341027B1 (no) 2002-04-23 2004-11-22 Tablett med høyt medikamentinnhold og fremgangsmåte for fremstilling derav

Country Status (31)

Country Link
US (6) US20050267125A1 (no)
EP (1) EP1501485B1 (no)
JP (4) JP2005529126A (no)
KR (1) KR100728846B1 (no)
CN (2) CN1646103A (no)
AR (3) AR039335A1 (no)
AT (1) ATE374016T1 (no)
AU (1) AU2003229705C1 (no)
BR (1) BR0309528A (no)
CA (1) CA2483199C (no)
CY (1) CY1106996T1 (no)
DE (1) DE60316552T2 (no)
DK (1) DK1501485T3 (no)
ES (1) ES2290457T3 (no)
GB (1) GB0209265D0 (no)
GE (1) GEP20094627B (no)
HR (1) HRP20040996B1 (no)
IL (1) IL164678A (no)
MX (1) MXPA04010496A (no)
MY (1) MY136406A (no)
NO (1) NO341027B1 (no)
NZ (1) NZ536046A (no)
PE (1) PE20031045A1 (no)
PL (1) PL199779B1 (no)
PT (1) PT1501485E (no)
RU (2) RU2363450C2 (no)
SI (1) SI1501485T1 (no)
TN (1) TNSN04213A1 (no)
TW (1) TWI350184B (no)
WO (1) WO2003090720A1 (no)
ZA (1) ZA200408441B (no)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
EP1720853B2 (en) 2004-02-11 2023-06-28 Natco Pharma Limited Pharmaceutical compositions of the 2 crystalline form of imatinib mesylate for use in the treatment of chronic myelogenous leukemia
WO2006040779A2 (en) * 2004-10-11 2006-04-20 Natco Pharma Limited Controlled release gastric floating matrix formulation containing imatinib
MX2007010856A (es) 2005-03-07 2007-11-12 Bayer Healthcare Ag Composicion farmaceutica que comprende una difenilurea sustituida con omega-carboxiarilo para el tratamiento del cancer.
MY148074A (en) * 2005-05-10 2013-02-28 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant
BRPI0611409B8 (pt) 2005-05-26 2021-05-25 Dainippon Sumitomo Pharma Co preparação oral compreendendo lurasidona
ES2334933T3 (es) 2005-08-15 2010-03-17 Siegfried Generics International Ag Comprimido recubierto o granulado que contiene una piridilpirimidina.
CN101951889A (zh) * 2006-09-01 2011-01-19 特瓦制药工业有限公司 伊马替尼组合物
AU2007299764B2 (en) 2006-09-22 2011-10-13 Novartis Ag Method of optimizing the treatment of Philadelphia-positive leukemia with Abl tyrosine kinase inhibitors
EP1920767A1 (en) * 2006-11-09 2008-05-14 Abbott GmbH & Co. KG Melt-processed imatinib dosage form
BRPI0817946A2 (pt) * 2007-09-25 2015-05-05 Teva Pharma Composições de imatinibe estável
PT2217205E (pt) 2007-11-06 2015-06-08 Novartis Ag Composições farmacêuticas de dupla ação baseadas nos antagonistas dos recetores de angiotensina e inibidores (arb) da endopeptidase neutra (nep)
EA201500525A1 (ru) 2008-06-27 2015-11-30 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Материалы и способы для подавления и/или лечения нейрофибромы и пограничных опухолей
WO2010065433A1 (en) 2008-12-01 2010-06-10 Novartis Ag Method of optimizing the treatment of philadelphia-positive leukemia with imatinib mesylate
PL389357A1 (pl) 2009-10-22 2011-04-26 Tomasz Koźluk Sole imatinibu z pochodnymi kwasów winowych i sposób ich wytwarzania
PL390611A1 (pl) 2010-03-04 2011-09-12 Tomasz Koźluk Sposób otrzymywania polimorficznej formy alfa i nowa forma polimorficzna mesylanu imatinibu
US20130085145A1 (en) * 2010-06-21 2013-04-04 Suven Life Sciences Limited Imatinib mesilate pharmaceutical tablet
WO2011160798A1 (en) * 2010-06-21 2011-12-29 Zaklady Farmaceutyczne Polpharma Sa Pharmaceutical compositions comprising imatinib or pharmaceutically acceptable salt thereof and processes for the manufacture thereof
RU2013110058A (ru) 2010-08-11 2014-09-20 Синтон Б.В. Фармацевтический гранулят, содержащий иматиниба мезилат
TR201010618A2 (tr) 2010-12-20 2012-07-23 Bi̇lgi̇ç Mahmut İmatinib içeren bir oral dozaj formu ve bu oral dozaj formunun üretimi
CN102552268A (zh) * 2010-12-23 2012-07-11 天津泰普药品科技发展有限公司 一种含有α晶型甲磺酸伊马替尼的药物制剂
PL394169A1 (pl) 2011-03-09 2012-09-10 Adamed Spółka Z Ograniczoną Odpowiedzialnością Kompozycja farmaceutyczna metanosulfonianu imatinibu do napełniania jednostkowych postaci dawkowania oraz sposób jej wytwarzania
US9750700B2 (en) 2011-06-22 2017-09-05 Natco Pharma Limited Imatinib mesylate oral pharmaceutical composition and process for preparation thereof
CN102349874B (zh) * 2011-08-26 2013-04-17 石药集团中奇制药技术（石家庄）有限公司 一种甲磺酸伊马替尼组合物及其制备方法
CN102349875A (zh) * 2011-10-11 2012-02-15 浙江华海药业股份有限公司 甲磺酸伊马替尼片的制备方法
PH12014500897A1 (en) 2011-10-28 2019-10-07 Novartis Ag Method of treating gastrointestinal stromal tumors
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
EP2782560A1 (en) 2011-11-24 2014-10-01 Imuneks Farma Ilaç Sanayi Ve Ticaret A.S. Imatinib solid dosage forms reconstituted just before use
KR101428149B1 (ko) * 2011-12-23 2014-08-08 씨제이헬스케어 주식회사 이매티닙메실산염 함유 과립, 이를 포함하는 경구용 속방성 정제 조성물 및 그것의 제조방법
IN2014DN07898A (no) 2012-02-21 2015-04-24 Ranbaxy Lab Ltd
GB201204810D0 (en) 2012-03-20 2012-05-02 Pharos Pharmaceutical Oriented Services Ltd Pharmaceutical compositions
JP5928159B2 (ja) * 2012-05-28 2016-06-01 ニプロ株式会社 医薬組成物
BR112015000349A2 (pt) 2012-07-11 2017-06-27 Novartis Ag método de tratamento de tumores estromais gastrointestinais
RU2517216C2 (ru) * 2012-08-22 2014-05-27 Закрытое Акционерное Общество "БИОКАД" (ЗАО "БИОКАД") Фармацевтическая композиция иматиниба или его фармацевтически приемлемой соли, способ ее получения и способ(ы) лечения
GB201304699D0 (en) 2013-03-15 2013-05-01 Remedica Ltd Pharmaceutical compositions
KR101520792B1 (ko) * 2013-04-10 2015-05-15 보령제약 주식회사 고부하 이매티닙 정제
EP2803353B1 (en) 2013-05-14 2018-05-23 Hetero Research Foundation Compositions of Imatinib
CN104749226A (zh) * 2013-12-25 2015-07-01 辰欣药业股份有限公司 一种用电位滴定法测定甲磺酸伊马替尼含量的方法
WO2017078647A1 (en) 2015-11-05 2017-05-11 Koçak Farma Ilaç Ve Kimya Sanayi Anonim Şirketi Pharmaceutical compositions of imatinib
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
EP3257499A1 (en) 2016-06-17 2017-12-20 Vipharm S.A. Process for preparation of imatinib methanesulfonate capsules
WO2019016673A2 (en) 2017-07-20 2019-01-24 Kashiv Pharma Llc STABLE PHARMACEUTICAL COMPOSITION OF ORAL ADMINISTRATION OF IMATINIB
MX2022000418A (es) 2019-07-15 2022-02-10 Intas Pharmaceuticals Ltd Composicion farmaceutica de imatinib.
BR112023009427A2 (pt) * 2020-12-01 2024-02-06 Lg Chemical Ltd Formulação oral que compreende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico e método de preparação da mesma
AR126164A1 (es) * 2021-06-17 2023-09-27 Lg Chemical Ltd Formulación compuesta para dosificación oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH176497A (de) 1934-09-14 1935-04-15 Schmid Ernst Alarmvorrichtung.
US3453368A (en) * 1966-01-13 1969-07-01 Hoffmann La Roche Smaller high potency compressed tablets of ascorbic acid
US3751277A (en) * 1971-03-24 1973-08-07 Dow Chemical Co Tablet coating process and composition
US4562024A (en) 1982-07-06 1985-12-31 Sterling Drug Inc. Process for preparing granulate containing poorly compressible medicinally active matter
US4639458A (en) 1985-01-22 1987-01-27 Merck & Co., Inc. Tablet and formulation
US4666705A (en) * 1985-06-03 1987-05-19 E. R. Squibb & Sons, Inc. Controlled release formulation
US4861598A (en) 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
EP0277092B1 (de) * 1987-01-14 1992-01-29 Ciba-Geigy Ag Therapeutisches System für schwerlösliche Wirkstoffe
JPS63267731A (ja) * 1987-04-23 1988-11-04 Asahi Chem Ind Co Ltd 錠剤組成物
WO1989000424A1 (en) 1987-07-22 1989-01-26 Leo Pharmaceutical Products B.V. Fusidic acid useful in the treatment of aids
YU120988A (en) * 1988-06-23 1990-06-30 Lek Tovarna Farmacevtskih Process for preparing new dispersion pills of cimetidine
US5368864A (en) 1988-11-25 1994-11-29 Henning Berlin Gmbh Chemie- Und Pharmawerk Formulation of oxypurinol and/or its alkali and alkaline earth salts
US4911921A (en) 1989-02-02 1990-03-27 Mallinckrodt, Inc. High ibuprofen content granulations
DE4031881C2 (de) 1990-10-08 1994-02-24 Sanol Arznei Schwarz Gmbh Lösungsmittelfreie, oral zu verabreichende pharmazeutische Zubereitung mit verzögerter Wirkstoffreisetzung und Verfahren zu deren Herstellung
TW225528B (no) * 1992-04-03 1994-06-21 Ciba Geigy Ag
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
IL109770A0 (en) 1993-05-29 1994-11-28 Smithkline Beecham Corp Thermal infusion process for preparing controlled release solid dosage forms of medicaments for oral administration and controlled release solid dosage forms of medicaments prepared thereby
US5635208A (en) 1993-07-20 1997-06-03 Mcneil-Ppc, Inc. Granulation process for producing an acetaminophen and diphenhydramine hydrochloride composition and composition produced by same
US5506248A (en) * 1993-08-02 1996-04-09 Bristol-Myers Squibb Company Pharmaceutical compositions having good dissolution properties
US5543520A (en) 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
AU683092B2 (en) 1993-10-12 1997-10-30 Mitsubishi-Tokyo Pharmaceuticals, Inc. Tablet containing enteric granules
US5605889A (en) 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
JP4334616B2 (ja) * 1994-09-22 2009-09-30 ナームローゼ・フエンノートチヤツプ・オルガノン 湿式粒状化による投与単位体を製造する方法
ES2079327B1 (es) 1994-12-13 1996-08-01 Lilly Sa Formulaciones farmaceuticas de cefaclor.
US6106865A (en) 1995-01-09 2000-08-22 Edward Mendell Co., Inc. Pharmaceutical excipient having improved compressibility
GB9501127D0 (en) 1995-01-20 1995-03-08 Wellcome Found Tablet
US5994348A (en) 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
TW442301B (en) 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
US5805889A (en) * 1995-10-20 1998-09-08 Sun Microsystems, Inc. System and method for integrating editing and versioning in data repositories
US6123964A (en) 1995-10-27 2000-09-26 Merck & Co., Inc. Wet granulation formulation of a growth hormone secretagogue
IL125214A0 (en) 1996-02-29 1999-03-12 Fujisawa Pharmaceutical Co Beta-lactam antibiotic-containing tablet and method for producing the same
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US20030124187A1 (en) * 1997-02-14 2003-07-03 Smithkline Beecham Laboratoires Pharmaceutiques, Pharmaceutical formulations comprising amoxycillin and clavulanate
JP3212531B2 (ja) * 1997-03-21 2001-09-25 信越化学工業株式会社 低置換度ヒドロキシプロピルセルロース、低置換度ヒドロキシプロピルセルロース崩壊剤及びその製造方法
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
FI109088B (fi) 1997-09-19 2002-05-31 Leiras Oy Tabletti ja menetelmä sen valmistamiseksi
PL340587A1 (en) 1997-11-17 2001-02-12 Smithkline Beecham Corp Oral preparations of high therapeutic substance content with instantaneous or modifiable release of such substance and methods of obtaining them
DE19758100B4 (de) * 1997-12-18 2006-05-04 Lichtwer Pharma Ag Verfahren zum Herstellen von Pflanzenextrakt enthaltenden pharmazeutischen Formulierungen
JP2002505269A (ja) 1998-03-06 2002-02-19 エウランド インターナショナル ソシエタ ペル アチオニ 急速崩壊錠剤
UA72207C2 (uk) 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
US20010014352A1 (en) 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
CA2239931A1 (en) 1998-07-15 2000-01-15 Bernard Charles Sherman Pharmaceutical tablet comprising norfloxacin
DK1105105T3 (da) * 1998-08-12 2006-07-17 Altana Pharma Ag Oral administrationsform til pyridin-2-ylmethylsulfinyl-1H-benzimidazoler
FR2785538B1 (fr) 1998-11-06 2004-04-09 Prographarm Laboratoires Comprime a delitement rapide perfectionne
JP4809978B2 (ja) 1998-11-10 2011-11-09 バイエル・シエリング・フアーマ・アクチエンゲゼルシヤフト 製薬学的モキシフロキサシン調製物
US6498153B1 (en) * 1998-12-31 2002-12-24 Akzo Nobel N.V. Extended release growth promoting two component composition
IT1311907B1 (it) 1999-04-06 2002-03-20 Zambon Spa Compresse deglutibili ad alto contenuto di n-acetilcisteina.
DK1200090T3 (da) 1999-08-03 2013-11-25 Icos Corp Farmaceutisk formulering omfattende en beta-carbolin og dens anvendelse til behandling af seksuel dysfunktion
US6294198B1 (en) * 1999-08-24 2001-09-25 Purepac Pharmaceutical Co. Pharmaceutical tablet formulation containing gabapentin with improved physical and chemical characteristics and method of making the same
US6264983B1 (en) 1999-09-16 2001-07-24 Rhodia, Inc. Directly compressible, ultra fine acetaminophen compositions and process for producing same
US6582721B1 (en) 1999-09-17 2003-06-24 Alcon, Inc. Stable carotene-xanthophyll beadlet compositions and methods of use
JP2001139462A (ja) 1999-11-10 2001-05-22 Dai Ichi Seiyaku Co Ltd 新規製剤
HRP20010582A2 (en) * 1999-12-08 2002-08-31 Pharmacia Corp Valdecoxib compositions
BR0016236A (pt) 1999-12-09 2002-12-24 Boots Co Plc Agentes terapêuticos
ITMI992711A1 (it) * 1999-12-27 2001-06-27 Novartis Ag Composti organici
DE10003757A1 (de) * 2000-01-28 2001-08-02 Knoll Ag Ibuprofen-Wirkstoffzubereitung
HUP0204417A3 (en) 2000-03-03 2005-03-29 Ranbaxy Lab Ltd Oral ciprofloxacin-composition of controlled release
DK1265608T3 (da) 2000-03-22 2008-12-08 Pharmacia & Upjohn Co Llc Oxazolidinon tabletformulering
DE10015479A1 (de) 2000-03-29 2001-10-11 Basf Ag Feste orale Darreichungsformen mit retardierter Wirkstofffreisetzung und hoher mechanischer Stabilität
CN1651087A (zh) 2000-04-12 2005-08-10 诺瓦提斯公司 有机化合物的联合形式
EP1296677A2 (en) 2000-06-22 2003-04-02 Novartis AG Solid valsartan pharmaceutical compositions
JP4698000B2 (ja) 2000-06-27 2011-06-08 旭化成ケミカルズ株式会社 水易溶性薬物含有錠剤
DE60238665D1 (de) 2001-02-27 2011-02-03 Senju Pharma Co Arzneimittelfreisetzungssystem aus einem biologisch abbaubaren polymer
EP1496908B1 (en) * 2002-04-10 2008-02-20 Virginia Commonwealth University Combination of glivec(sti571) with a cyclin-dependent kinase inhibitor, especially flavopiridol in the treatment of cancer
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
IL164678A0 (en) 2005-12-18
JP5752107B2 (ja) 2015-07-22
EP1501485B1 (en) 2007-09-26
BR0309528A (pt) 2005-02-15
EP1501485A1 (en) 2005-02-02
SI1501485T1 (sl) 2008-08-31
AR039335A1 (es) 2005-02-16
CY1106996T1 (el) 2012-09-26
JP2010031019A (ja) 2010-02-12
DK1501485T3 (da) 2007-12-27
HK1073253A1 (en) 2005-09-30
AR084101A2 (es) 2013-04-24
KR20040101550A (ko) 2004-12-02
US9011911B2 (en) 2015-04-21
CN101653424A (zh) 2010-02-24
PL199779B1 (pl) 2008-10-31
US20050267125A1 (en) 2005-12-01
JP2005529126A (ja) 2005-09-29
HRP20040996B1 (hr) 2010-11-30
AU2003229705A1 (en) 2003-11-10
AR072755A2 (es) 2010-09-22
AU2003229705B2 (en) 2007-01-25
US20100203133A1 (en) 2010-08-12
TWI350184B (en) 2011-10-11
DE60316552D1 (de) 2007-11-08
GEP20094627B (en) 2009-03-10
JP2015143250A (ja) 2015-08-06
JP5798269B2 (ja) 2015-10-21
ZA200408441B (en) 2005-08-31
GB0209265D0 (en) 2002-06-05
US20160101105A1 (en) 2016-04-14
HRP20040996A2 (en) 2005-06-30
MY136406A (en) 2008-09-30
MXPA04010496A (es) 2004-12-13
DE60316552T2 (de) 2008-07-03
RU2405540C1 (ru) 2010-12-10
US20120177737A1 (en) 2012-07-12
US20150209291A1 (en) 2015-07-30
TNSN04213A1 (en) 2007-03-12
CN1646103A (zh) 2005-07-27
ES2290457T3 (es) 2008-02-16
KR100728846B1 (ko) 2007-06-14
PL371495A1 (en) 2005-06-27
NZ536046A (en) 2007-08-31
TW200404009A (en) 2004-03-16
PT1501485E (pt) 2007-12-18
IL164678A (en) 2014-02-27
CA2483199A1 (en) 2003-11-06
CA2483199C (en) 2010-08-17
JP2013079271A (ja) 2013-05-02
WO2003090720A1 (en) 2003-11-06
RU2004134323A (ru) 2005-08-10
US20140135340A1 (en) 2014-05-15
ATE374016T1 (de) 2007-10-15
AU2003229705C1 (en) 2017-09-07
NO341027B1 (no) 2017-08-07
PE20031045A1 (es) 2004-02-10
RU2363450C2 (ru) 2009-08-10

Similar Documents

Publication Publication Date Title
NO20045072L (no) Tablett med hoyt medikamentinnhold
NO20052335L (no) Dispergerbare deferacirox-tabletter
NO20064670L (no) Galeniske formuleringer av organiske forbindelser
NO20082265L (no) Dispergerbare tabletter som innbefatter deferasirox
NO20062004L (no) Forlenget frigjoring farmasoytiske blandinger omfattene aplindor og derivater derav
ATE424810T1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
MY140576A (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms
NO20062713L (no) 2,6 bisheteroaryl-4-aminopyrimidiner som adenosin reseptor antagonister
SE0302760D0 (sv) New compounds
NO20052496L (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og anvendelse derav som medikamenter.
UA109421C2 (uk) Фармацевтична композиція, яка містить ліганди сигма-рецептора
NO20072515L (no) 2-amido-4-fenyltnazolderivater, fremstilling og terapeutsik anvendelse derav
NO20080827L (no) Faste doseringsformuleringer av narkotiske legemidler som har forbedret bukal adsorpsjon
NO20043367L (no) Oralt farmasoytisk preparat
DK1207756T3 (da) Anvendelse af spinosad eller en formulering, der omfatter spinosad
TW200603841A (en) Dispersible tablets comprising a benzoic acid derivative
HRP20110162A8 (hr) Spojevi koji sadrže amlodipin i bisoprolol
NO20055631L (no) Doseringsform inneholdende pantoprazol som aktiv ingrediens
TW200503785A (en) Dosage form containing (S)-pantoprazole as active ingredient
NO20055254L (no) Farmasoytisk kombinasjon for behandling av spastisitet og/eller smerte
MXPA05008190A (es) Derivado de oligosacarido.
TR200802061A2 (tr) Yüksek oranda aktif madde içeren farmasötlk formülasyon.
EP1734046A4 (en) radiosensitizer
CA2409845A1 (en) Active substance combination containing a compound with an opioid effect and at least one further compound of formula i
NO20052413L (no) Substituted aralkyl derivatives

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: NOVARTIS PHARMA AG, CH

MK1K Patent expired